Piramal Pharma Limited's board will meet on April 28, 2026, to approve audited standalone and consolidated financial results for Q4 and FY ending March 31, 2026.
The company's trading window for securities is closed from April 1, 2026, and will remain closed until April 30, 2026, inclusive.
This intimation is a mandatory disclosure made pursuant to Regulation 29 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.